Amy R. Peck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amy R. Peck has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hallgeir Rui
Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania
4 shared publications - Thai H Tran
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107, USA
3 shared publications - Albert J Kovatich
MDR Global Systems, LLC, 425 Park Place, Windber, PA 15963, USA
2 shared publications - Boris Freydin
Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Thomas Jefferson University, 1015 Chestnut Street, Philadelphia, PA 19107, USA
2 shared publications - Chengbao Liu
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107, USA
2 shared publications - Craig D Shriver
Department of Surgery, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20814, USA
2 shared publications
Latest Publications
- Open Access
- 15 March 2025
- Published by Springer Nature in Statistics and Computing
- Vol. 35 (3) , 1-18
Estimation and model selection for finite mixtures of Tukey’s g- &-h distributions
A finite mixture of distributions is a popular statistical model, which is especially meaningful when the population of interest may include distinct subpopulations. This work is motivated by analysis of protein expression levels quantified using immunofluorescence immunohistochemistry assays of human tissues. The distributions of cellular protein expression levels in a tissue often exhibit multimodality, skewness and heavy tails, but there is a substantial variability between distributions in different tissues from different subjects, while some of these mixture distributions include components consistent with the assumption of a normal distribution. To accommodate such diversity, we propose a mixture of 4-parameter Tukey’s g- &-h distributions for fitting finite mixtures with both Gaussian and non-Gaussian components. Tukey’s g- &-h distribution is a flexible model that allows variable degree of skewness and kurtosis in mixture components, including normal distribution as a particular case. Since the likelihood of the Tukey’s g- &-h mixtures does not have a closed analytical form, we propose a quantile least Mahalanobis distance (QLMD) estimator for parameters of such mixtures. QLMD is an indirect estimator minimizing the Mahalanobis distance between the sample and model-based quantiles, and its asymptotic properties follow from the general theory of indirect estimation. We have developed a stepwise algorithm to select a parsimonious Tukey’s g- &-h mixture model and implemented all proposed methods in the R package QuantileGH available on CRAN. A simulation study was conducted to evaluate performance of the Tukey’s g- &-h mixtures and compare to performance of mixtures of skew-normal or skew-t distributions. The Tukey’s g- &-h mixtures were applied to model cellular expressions of Cyclin D1 protein in breast cancer tissues, and resulting parameter estimates evaluated as predictors of progression-free survival.
- 15 March 2025
- Published by Springer Nature in Statistics and Computing
- Vol. 35 (3) , 1-18
Open AccessEstimation and model selection for finite mixtures of Tukey’s g- &-h distributions
A finite mixture of distributions is a popular statistical model, which is especially meaningful when the population of interest may include distinct subpopulations. This work is motivated by analysis of protein expression levels quantified using immunofluorescence immunohistochemistry assays of human tissues. The distributions of cellular protein expression levels in a tissue often exhibit multimodality, skewness and heavy tails, but there is a substantial variability between distributions in different tissues from different subjects, while some of these mixture distributions include components consistent with the assumption of a normal distribution. To accommodate such diversity, we propose a mixture of 4-parameter Tukey’s g- &-h distributions for fitting finite mixtures with both Gaussian and non-Gaussian components. Tukey’s g- &-h distribution is a flexible model that allows variable degree of skewness and kurtosis in mixture components, including normal distribution as a particular case. Since the likelihood of the Tukey’s g- &-h mixtures does not have a closed analytical form, we propose a quantile least Mahalanobis distance (QLMD) estimator for parameters of such mixtures. QLMD is an indirect estimator minimizing the Mahalanobis distance between the sample and model-based quantiles, and its asymptotic properties follow from the general theory of indirect estimation. We have developed a stepwise algorithm to select a parsimonious Tukey’s g- &-h mixture model and implemented all proposed methods in the R package QuantileGH available on CRAN. A simulation study was conducted to evaluate performance of the Tukey’s g- &-h mixtures and compare to performance of mixtures of skew-normal or skew-t distributions. The Tukey’s g- &-h mixtures were applied to model cellular expressions of Cyclin D1 protein in breast cancer tissues, and resulting parameter estimates evaluated as predictors of progression-free survival.
- Open Access
- 3 September 2013
- Published by Springer Nature in Breast Cancer Research
- Vol. 15 (5) , R73
Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment
Introduction: Emerging evidence in estrogen receptor-positive breast cancer supports the notion that prolactin-Stat5 signaling promotes survival and maintenance of differentiated luminal cells, and loss of nuclear tyrosine phosphorylated Stat5 (Nuc-pYStat5) in clinical breast cancer is associated with increased risk of antiestrogen therapy failure. However, the molecular mechanisms underlying loss of Nuc-pYStat5 in breast cancer remain poorly defined. Methods: We investigated whether moderate extracellular acidosis of pH 6.5 to 6.9 frequently observed in breast cancer inhibits prolactin-Stat5 signaling, using in vitro and in vivo experimental approaches combined with quantitative immunofluorescence protein analyses to interrogate archival breast cancer specimens. Results: Moderate acidosis at pH 6.8 potently disrupted signaling by receptors for prolactin but not epidermal growth factor, oncostatin M, IGF1, FGF or growth hormone. In breast cancer specimens there was mutually exclusive expression of Nuc-pYStat5 and GLUT1, a glucose transporter upregulated in glycolysis-dependent carcinoma cells and an indirect marker of lactacidosis. Mutually exclusive expression of GLUT1 and Nuc-pYStat5 occurred globally or regionally within tumors, consistent with global or regional acidosis. All prolactin-induced signals and transcripts were suppressed by acidosis, and the acidosis effect was rapid and immediately reversible, supporting a mechanism of acidosis disruption of prolactin binding to receptor. T47D breast cancer xenotransplants in mice displayed variable acidosis (pH 6.5 to 6.9) and tumor regions with elevated GLUT1 displayed resistance to exogenous prolactin despite unaltered levels of prolactin receptors and Stat5. Conclusions: Moderate extracellular acidosis effectively blocks prolactin signaling in breast cancer. We propose that acidosis-induced prolactin resistance represents a previously unrecognized mechanism by which breast cancer cells may escape homeostatic control.
- 3 September 2013
- Published by Springer Nature in Breast Cancer Research
- Vol. 15 (5) , R73
Open AccessProlactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment
Introduction: Emerging evidence in estrogen receptor-positive breast cancer supports the notion that prolactin-Stat5 signaling promotes survival and maintenance of differentiated luminal cells, and loss of nuclear tyrosine phosphorylated Stat5 (Nuc-pYStat5) in clinical breast cancer is associated with increased risk of antiestrogen therapy failure. However, the molecular mechanisms underlying loss of Nuc-pYStat5 in breast cancer remain poorly defined. Methods: We investigated whether moderate extracellular acidosis of pH 6.5 to 6.9 frequently observed in breast cancer inhibits prolactin-Stat5 signaling, using in vitro and in vivo experimental approaches combined with quantitative immunofluorescence protein analyses to interrogate archival breast cancer specimens. Results: Moderate acidosis at pH 6.8 potently disrupted signaling by receptors for prolactin but not epidermal growth factor, oncostatin M, IGF1, FGF or growth hormone. In breast cancer specimens there was mutually exclusive expression of Nuc-pYStat5 and GLUT1, a glucose transporter upregulated in glycolysis-dependent carcinoma cells and an indirect marker of lactacidosis. Mutually exclusive expression of GLUT1 and Nuc-pYStat5 occurred globally or regionally within tumors, consistent with global or regional acidosis. All prolactin-induced signals and transcripts were suppressed by acidosis, and the acidosis effect was rapid and immediately reversible, supporting a mechanism of acidosis disruption of prolactin binding to receptor. T47D breast cancer xenotransplants in mice displayed variable acidosis (pH 6.5 to 6.9) and tumor regions with elevated GLUT1 displayed resistance to exogenous prolactin despite unaltered levels of prolactin receptors and Stat5. Conclusions: Moderate extracellular acidosis effectively blocks prolactin signaling in breast cancer. We propose that acidosis-induced prolactin resistance represents a previously unrecognized mechanism by which breast cancer cells may escape homeostatic control.
- Open Access
- 12 June 2013
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 59
Global profiling of prolactin-modulated transcripts in breast cancer in vivo
Background: Prolactin (PRL) is essential for normal mammary gland development. PRL promotes mammary tumor formation in rodents and elevated serum prolactin is associated with increased risk of estrogen-receptor positive breast cancer in women. On the other hand, PRL may also exert pro-differentiation effects and act to suppress invasive features of established breast cancer. Previously published limited global transcript profiling analyses of prolactin-regulated gene expression in human breast cancer cells have exclusively been performed in vitro. The present study aimed to shed new light on how PRL modulates estrogen receptor (ER)-positive breast cancer through global transcript profiling of a human breast cancer xenograft model in vivo. Methods: The prolactin-responsive human T47D breast cancer cell line was xenotransplanted into nude mice and global transcript profiling was carried out following treatment with or without human PRL for 48 h. A subset of PRL-modulated transcripts was further validated using qRT-PCR and immunohistochemistry. Results: The in vivo analyses identified 130 PRL-modulated transcripts, 75 upregulated and 55 downregulated, based on fold change >1.6 and P-value in vitro. The selected PRL-modulated transcripts were tested for dependence on Stat5, Jak1 or Jak2 activation, and for co-regulation by 17β-estradiol (E2). The protein encoded by one of the PRL-regulated transcripts, PTHrP, was examined in a panel of 92 human breast cancers and found by in situ quantitative immunofluorescence analysis to be highly positively correlated with nuclear localized and tyrosine phosphorylated Stat5. Gene Ontology analysis revealed that PRL-upregulated genes were enriched in pathways involved in differentiation. Finally, a gene signature based on PRL-upregulated genes was associated with prolonged relapse-free and metastasis-free survival in breast cancer patients. Conclusions: This global analysis identified and validated a panel of PRL-modulated transcripts in an ER-positive human breast cancer xenotransplant model, which may have value as markers of relapse-free and metastasis-free survival. Gene products identified in the present study may facilitate ongoing deciphering of the pleiotropic effects of PRL on human breast cancer.
- 12 June 2013
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 59
Open AccessGlobal profiling of prolactin-modulated transcripts in breast cancer in vivo
Background: Prolactin (PRL) is essential for normal mammary gland development. PRL promotes mammary tumor formation in rodents and elevated serum prolactin is associated with increased risk of estrogen-receptor positive breast cancer in women. On the other hand, PRL may also exert pro-differentiation effects and act to suppress invasive features of established breast cancer. Previously published limited global transcript profiling analyses of prolactin-regulated gene expression in human breast cancer cells have exclusively been performed in vitro. The present study aimed to shed new light on how PRL modulates estrogen receptor (ER)-positive breast cancer through global transcript profiling of a human breast cancer xenograft model in vivo. Methods: The prolactin-responsive human T47D breast cancer cell line was xenotransplanted into nude mice and global transcript profiling was carried out following treatment with or without human PRL for 48 h. A subset of PRL-modulated transcripts was further validated using qRT-PCR and immunohistochemistry. Results: The in vivo analyses identified 130 PRL-modulated transcripts, 75 upregulated and 55 downregulated, based on fold change >1.6 and P-value in vitro. The selected PRL-modulated transcripts were tested for dependence on Stat5, Jak1 or Jak2 activation, and for co-regulation by 17β-estradiol (E2). The protein encoded by one of the PRL-regulated transcripts, PTHrP, was examined in a panel of 92 human breast cancers and found by in situ quantitative immunofluorescence analysis to be highly positively correlated with nuclear localized and tyrosine phosphorylated Stat5. Gene Ontology analysis revealed that PRL-upregulated genes were enriched in pathways involved in differentiation. Finally, a gene signature based on PRL-upregulated genes was associated with prolonged relapse-free and metastasis-free survival in breast cancer patients. Conclusions: This global analysis identified and validated a panel of PRL-modulated transcripts in an ER-positive human breast cancer xenotransplant model, which may have value as markers of relapse-free and metastasis-free survival. Gene products identified in the present study may facilitate ongoing deciphering of the pleiotropic effects of PRL on human breast cancer.
- Open Access
- 4 October 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (5) , R130
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
Introduction: Signal transducer and activator of transcripton-5a (Stat5a) and its close homologue, Stat5b, mediate key physiological effects of prolactin and growth hormone in mammary glands. In breast cancer, loss of nuclear localized and tyrosine phosphorylated Stat5a/b is associated with poor prognosis and increased risk of antiestrogen therapy failure. Here we quantify for the first time levels of Stat5a and Stat5b over breast cancer progression, and explore their potential association with clinical outcome. Methods: Stat5a and Stat5b protein levels were quantified in situ in breast-cancer progression material. Stat5a and Stat5b transcript levels in breast cancer were correlated with clinical outcome in 936 patients. Stat5a protein was further quantified in four archival cohorts totaling 686 patients with clinical outcome data by using multivariate models. Results: Protein levels of Stat5a but not Stat5b were reduced in primary breast cancer and lymph node metastases compared with normal epithelia. Low tumor levels of Stat5a but not Stat5b mRNA were associated with poor prognosis. Experimentally, only limited overlap between Stat5a- and Stat5b-modulated genes was found. In two cohorts of therapy-naïve, node-negative breast cancer patients, low nuclear Stat5a protein levels were an independent marker of poor prognosis. Multivariate analysis of two cohorts treated with antiestrogen monotherapy revealed that low nuclear Stat5a levels were associated with a more than fourfold risk of unfavorable outcome. Conclusions: Loss of Stat5a represents a new independent marker of poor prognosis in node-negative breast cancer and may be a predictor of response to antiestrogen therapy if validated in randomized clinical trials.
- 4 October 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (5) , R130
Open AccessLow levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
Introduction: Signal transducer and activator of transcripton-5a (Stat5a) and its close homologue, Stat5b, mediate key physiological effects of prolactin and growth hormone in mammary glands. In breast cancer, loss of nuclear localized and tyrosine phosphorylated Stat5a/b is associated with poor prognosis and increased risk of antiestrogen therapy failure. Here we quantify for the first time levels of Stat5a and Stat5b over breast cancer progression, and explore their potential association with clinical outcome. Methods: Stat5a and Stat5b protein levels were quantified in situ in breast-cancer progression material. Stat5a and Stat5b transcript levels in breast cancer were correlated with clinical outcome in 936 patients. Stat5a protein was further quantified in four archival cohorts totaling 686 patients with clinical outcome data by using multivariate models. Results: Protein levels of Stat5a but not Stat5b were reduced in primary breast cancer and lymph node metastases compared with normal epithelia. Low tumor levels of Stat5a but not Stat5b mRNA were associated with poor prognosis. Experimentally, only limited overlap between Stat5a- and Stat5b-modulated genes was found. In two cohorts of therapy-naïve, node-negative breast cancer patients, low nuclear Stat5a protein levels were an independent marker of poor prognosis. Multivariate analysis of two cohorts treated with antiestrogen monotherapy revealed that low nuclear Stat5a levels were associated with a more than fourfold risk of unfavorable outcome. Conclusions: Loss of Stat5a represents a new independent marker of poor prognosis in node-negative breast cancer and may be a predictor of response to antiestrogen therapy if validated in randomized clinical trials.